| 17/01/23 | 07:00:05 | 17 Jan 2023 | | Successful Completion of Fourth Dose Escalation |
| 16/01/23 | 10:15:56 | 16 Jan 2023 | | Block Listing Application to AIM |
| 19/12/22 | 07:00:07 | 19 Dec 2022 | | Avacta to Host Therapeutics Division Science Day |
| 08/11/22 | 07:01:01 | 8 Nov 2022 | | Director/PDMR Shareholding |
| 08/11/22 | 07:00:04 | 8 Nov 2022 | | Result of the Open Offer |
| 31/10/22 | 13:32:24 | 31 Oct 2022 | | Avacta to Present at Theranostics FAP Summit |
| 31/10/22 | 11:05:35 | 31 Oct 2022 | | Second Price Monitoring Extn |
| 31/10/22 | 11:00:24 | 31 Oct 2022 | | Price Monitoring Extension |
| 28/10/22 | 07:00:07 | 28 Oct 2022 | | Block Listing Six Monthly Return |
| 20/10/22 | 08:01:03 | 20 Oct 2022 | | Director/PDMR Shareholding |
| 20/10/22 | 08:01:01 | 20 Oct 2022 | | Admission of the Company’s Ordinary Shares |
| 20/10/22 | 07:00:05 | 20 Oct 2022 | | Posting of the Company’s Open Offer Circular |
| 18/10/22 | 11:49:01 | 18 Oct 2022 | | Result of Placing |
| 18/10/22 | 09:16:20 | 18 Oct 2022 | | Private CB and ABB Launch |
| 18/10/22 | 09:14:08 | 18 Oct 2022 | | Proposed acquisition of Launch Diagnostics |
| 29/09/22 | 07:00:11 | 29 Sept 2022 | | Interim Results for the Period Ended 30 June 2022 |
| 26/09/22 | 07:00:14 | 26 Sept 2022 | | Notice of Results |
| 05/09/22 | 07:00:06 | 5 Sept 2022 | | AVA6000 receives Orphan Drug Designation from FDA |
| 01/09/22 | 07:00:08 | 1 Sept 2022 | | Phase I study of AVA6000 advances to fourth cohort |
| 21/07/22 | 07:00:05 | 21 Jul 2022 | | AffyXell successfully completes funding round |
| 30/06/22 | 07:00:07 | 30 Jun 2022 | | LG Chem renews license triggers payment to Avacta |
| 29/06/22 | 09:05:35 | 29 Jun 2022 | | Second Price Monitoring Extn |
| 29/06/22 | 09:00:30 | 29 Jun 2022 | | Price Monitoring Extension |
| 29/06/22 | 07:00:06 | 29 Jun 2022 | | Second dose escalation in phase 1 trial of AVA6000 |
| 23/06/22 | 16:41:16 | 23 Jun 2022 | | Second Price Monitoring Extn |
| 23/06/22 | 16:36:18 | 23 Jun 2022 | | Price Monitoring Extension |
| 23/06/22 | 16:27:30 | 23 Jun 2022 | | Result of Annual General Meeting |
| 16/06/22 | 16:41:02 | 16 Jun 2022 | | Second Price Monitoring Extn |
| 16/06/22 | 16:36:14 | 16 Jun 2022 | | Price Monitoring Extension |
| 31/05/22 | 07:00:06 | 31 May 2022 | | Posting of Annual Report and Notice of AGM |
| 16/05/22 | 12:00:07 | 16 May 2022 | | AffyXell expands partnership with GenScript ProBio |
| 11/05/22 | 07:00:05 | 11 May 2022 | | London Therapeutics headquarters established |
| 06/05/22 | 07:00:07 | 6 May 2022 | | Block Listing Application to AIM (update) |
| 28/04/22 | 13:53:19 | 28 Apr 2022 | | Block Listing Application to AIM |
| 14/04/22 | 17:01:03 | 14 Apr 2022 | | Issue of Equity and Total Voting Rights |
| 14/04/22 | 11:29:20 | 14 Apr 2022 | | Issue of Equity and Total Voting Rights |
| 13/04/22 | 07:00:10 | 13 Apr 2022 | | AffyXell milestone and increased equity stake |
| 12/04/22 | 07:00:05 | 12 Apr 2022 | | Poster presented at the AACR available to download |
| 11/04/22 | 16:41:24 | 11 Apr 2022 | | Second Price Monitoring Extn |
| 11/04/22 | 16:35:32 | 11 Apr 2022 | | Price Monitoring Extension |
| 11/04/22 | 14:05:44 | 11 Apr 2022 | | Second Price Monitoring Extn |
| 11/04/22 | 14:00:58 | 11 Apr 2022 | | Price Monitoring Extension |
| 08/04/22 | 13:57:24 | 8 Apr 2022 | | Issue of Equity and Total Voting Rights |
| 08/04/22 | 07:00:04 | 8 Apr 2022 | | AffyXell partners with Biocytogen and KNTSC |
| 07/04/22 | 16:31:15 | 7 Apr 2022 | | Issue of Equity and Total Voting Rights |
| 06/04/22 | 07:00:07 | 6 Apr 2022 | | Preliminary Results |
| 30/03/22 | 16:41:09 | 30 Mar 2022 | | Second Price Monitoring Extn |
| 30/03/22 | 16:35:49 | 30 Mar 2022 | | Price Monitoring Extension |
| 30/03/22 | 07:00:06 | 30 Mar 2022 | | Notice of Results and Investor Presentation |
| 29/03/22 | 07:00:09 | 29 Mar 2022 | | AVA6000 data poster presentation at AACR |
